Logo image of ZNTL

ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZNTL - US98943L1070 - Common Stock

1.41 USD
+0.02 (+1.44%)
Last: 12/8/2025, 4:30:03 PM
1.43 USD
+0.02 (+1.42%)
After Hours: 12/8/2025, 4:30:03 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZNTL. ZNTL was compared to 531 industry peers in the Biotechnology industry. ZNTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ZNTL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZNTL has reported negative net income.
In the past year ZNTL has reported a negative cash flow from operations.
ZNTL had negative earnings in each of the past 5 years.
ZNTL had a negative operating cash flow in each of the past 5 years.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

ZNTL has a Return On Assets (-45.48%) which is in line with its industry peers.
ZNTL has a Return On Equity of -58.86%. This is in the better half of the industry: ZNTL outperforms 61.58% of its industry peers.
Industry RankSector Rank
ROA -45.48%
ROE -58.86%
ROIC N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZNTL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

6

2. Health

2.1 Basic Checks

ZNTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZNTL has been increased compared to 1 year ago.
ZNTL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ZNTL has an Altman-Z score of -4.67. This is a bad value and indicates that ZNTL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.67, ZNTL is not doing good in the industry: 61.77% of the companies in the same industry are doing better.
There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.67
ROIC/WACCN/A
WACC8.78%
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

ZNTL has a Current Ratio of 7.76. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.76, ZNTL is in the better half of the industry, outperforming 72.88% of the companies in the same industry.
A Quick Ratio of 7.76 indicates that ZNTL has no problem at all paying its short term obligations.
The Quick ratio of ZNTL (7.76) is better than 72.88% of its industry peers.
Industry RankSector Rank
Current Ratio 7.76
Quick Ratio 7.76
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.87% over the past year.
ZNTL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.76%.
EPS 1Y (TTM)25.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ZNTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.85% on average per year.
Based on estimates for the next years, ZNTL will show a very strong growth in Revenue. The Revenue will grow by 30.07% on average per year.
EPS Next Y18.41%
EPS Next 2Y11.51%
EPS Next 3Y8.44%
EPS Next 5Y12.85%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.89%
Revenue Next 5Y30.07%

3.3 Evolution

ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2027 2028 2029 2030 2031 2032 200M 400M 600M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZNTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZNTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.51%
EPS Next 3Y8.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZNTL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (12/8/2025, 4:30:03 PM)

After market: 1.43 +0.02 (+1.42%)

1.41

+0.02 (+1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-24 2026-03-24/amc
Inst Owners72.59%
Inst Owner Change-5.98%
Ins Owners12.12%
Ins Owner Change4.02%
Market Cap101.87M
Revenue(TTM)26.86M
Net Income(TTM)-148.84M
Analysts77.33
Price Target5.42 (284.4%)
Short Float %8.18%
Short Ratio7.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.44%
Min EPS beat(2)31.28%
Max EPS beat(2)37.6%
EPS beat(4)4
Avg EPS beat(4)24.17%
Min EPS beat(4)13.88%
Max EPS beat(4)37.6%
EPS beat(8)7
Avg EPS beat(8)26.27%
EPS beat(12)9
Avg EPS beat(12)13.53%
EPS beat(16)11
Avg EPS beat(16)12.04%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.14%
PT rev (3m)-14.14%
EPS NQ rev (1m)20.77%
EPS NQ rev (3m)20.77%
EPS NY rev (1m)15.62%
EPS NY rev (3m)15.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.79
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-1.86
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0.37
BVpS3.5
TBVpS3.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.48%
ROE -58.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.76
Quick Ratio 7.76
Altman-Z -4.67
F-Score3
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)79.15%
Cap/Depr(5y)368.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
EPS Next Y18.41%
EPS Next 2Y11.51%
EPS Next 3Y8.44%
EPS Next 5Y12.85%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.89%
Revenue Next 5Y30.07%
EBIT growth 1Y26.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.07%
EBIT Next 3Y8.71%
EBIT Next 5YN/A
FCF growth 1Y34.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.34%
OCF growth 3YN/A
OCF growth 5YN/A

ZENTALIS PHARMACEUTICALS INC / ZNTL FAQ

What is the ChartMill fundamental rating of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ZNTL.


Can you provide the valuation status for ZENTALIS PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ZENTALIS PHARMACEUTICALS INC (ZNTL). This can be considered as Overvalued.


Can you provide the profitability details for ZENTALIS PHARMACEUTICALS INC?

ZENTALIS PHARMACEUTICALS INC (ZNTL) has a profitability rating of 1 / 10.


What is the financial health of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

The financial health rating of ZENTALIS PHARMACEUTICALS INC (ZNTL) is 6 / 10.


What is the expected EPS growth for ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

The Earnings per Share (EPS) of ZENTALIS PHARMACEUTICALS INC (ZNTL) is expected to grow by 18.41% in the next year.